Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$332.29 ▲ +7.74
(+2.38%)
MKT CAP: $9.61B • VOL: 330.5K
52W L $184 52W H $383
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$279
MEDIAN
$372
MEAN
$379
HIGH
$452
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KRYS TAPE
KRYS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $402.07 | $382.13 | 2025-02-14 | $302.38 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $418.69 | $392.10 | 2025-02-06 | $312.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $378.81 | $365.52 | 2025-01-29 | $319.00 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $338.94 | — | 2025-01-17 | $325.64 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $292.42 | $315.68 | 2025-01-09 | $295.74 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $395.43 | $345.58 | 2024-12-18 | $289.09 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $322.32 | $335.61 | 2024-12-04 | $309.03 | -4.3% | 48% | C |